SELECTION OF LOCATORS IN AUTOMATED DESIGN OF FIXTURES FOR LOCATING WORKPIECES DURING MACHINING

Using the systematic approach, the possible basing schemes of the workpieces in the machining attachments have been discovered and systematized with a view to their use in automated design. The analysis shows that the use of the proposed systematization in computer-aided design is significantly more rational, since the structure reflects the sequence of choice of the optimal basing scheme - analysis of the theoretical basing scheme, analysis of the geometry of the workpiece, formation of the possible list of the basing schemes. An analysis was performed with the help of which the criteria for geometric compatibility were revealed, allowing to make a choice of a basing scheme, satisfying the geometric shape of the workpiece. An algorithm for selection of locators has been developed. The development is part of a system for automated design of fixtures for locating of workpieces during machining.

INCREASING THE QUALITY OF FORMING OF SPINNING DETAILS OF ALUMINUM ALLOYS BY CONTROLLING THE RESIDUAL STRESSES IN THEIR SURFACE LAYER

In the article are analyzed the effect of technological modes and processing parameters on the stress of spinning (cold flow turning) details of aluminum alloys. Аs the object of the study was used a detail of aluminum alloy AMg5, obtained after 3-stage spinning with intermediate heat treatments between the stages. As a control criterion was used non-destructive resistive electro contact method, based on the correlation between the integral electric and mechanical characteristics of metals and alloys – specific conductivity or electrical resistivity within the h-layer of the metal and the amount of deformation in the crystal lattice of the material due to the residual stresses

SOLVING FUNCTIONAL-TECHNOLOGICAL PROBLEMS USING A NON-PARAMETRIC APPROACH FOR CONTROL OF MICROGEOMETRY OF THE SURFACES OF DETAILS

In the article considers the effect of surface roughness on the functioning of a specific mechanism. In case of proven dependence of the studied functional property of surface microgeometry, a process of optimization of the sought parameter is carried out, in which the methods of mathematical analysis and theoretic foundations of technology of appliance and mechanical engineering are used for the basis of the theoretical studies. As control parameters of the specified optimal microgeometry, deciding the given task, the so-called non-parametric criteria are used, namely graphical of certain surface-profile functions

Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients

Seasonal influenza causes >200 000 annual hospitalizations in the United States. Current antiviral treatment options are limited to oral or inhaled agents. There is an urgent unmet need for intravenous antiviral treatments. Patients hospitalized with suspected influenza were randomized to 5-day treatment with intravenous peramivir (600 mg once daily) or placebo; all received the institution's standard of care (SOC) treatment. Time to clinical resolution and change in viral shedding in nasopharyngeal specimens were the primary and key secondary end points. Influenza infection was confirmed in 338 of 405 enrolled patients. At the time of a preplanned interim analysis, the primary efficacy analysis population comprised 121 patients who did not receive a concurrent neuraminidase inhibitor as part of the SOC. The median (95% confidence interval) time to clinical resolution was 42.5 (34.0-57.9) hours for peramivir versus 49.5 (40.0-61.9) hours for placebo (P = .97). A larger treatment effect was observed in patients with history of symptoms <48 hours or admitted to an intensive care unit. Greater reductions in viral shedding, based on median tissue culture infective dose, were observed in patients who received peramivir than in placebo recipients, although this difference was not statistically significant. The incidence and severity of adverse events and laboratory abnormalities were similar between the 2 treatment groups. The study was terminated for futility after a preplanned interim analysis. A significant clinical benefit was not demonstrated for peramivir plus SOC compared with placebo plus SOC. Peramivir was generally safe and well tolerated. These findings highlight the challenges in designing studies to evaluate influenza antiviral agents in a hospitalized setting. Clinical Trials Registration. NCT0095877

Pitolisant for Residual Excessive Daytime Sleepiness in OSA Patients Adhering to CPAP

International audienceBackground: Excessive daytime sleepiness (EDS) in individuals with OSA syndrome persisting despite good adherence to CPAP is a disabling condition. Pitolisant is a selective histamine H3-receptor antagonist with wake-promoting effects.Research question: Is pitolisant effective and safe for reducing daytime sleepiness in individuals with moderate to severe OSA adhering to CPAP treatment but experiencing residual EDS?Study design and methods: In a multicenter, double-blind, randomized (3:1), placebo-controlled, parallel-design trial, pitolisant was titrated individually at up to 20 mg/day and taken over 12 weeks. The primary end point was change in the Epworth Sleepiness Scale (ESS) score in the intention-to-treat population. Key secondary end points were maintenance of wakefulness assessed by the Oxford Sleep Resistance Test, Clinical Global Impressions scale of severity, the patient's global opinion, EuroQoL quality-of-life questionnaire score, Pichot fatigue questionnaire score, and safety.Results: Two hundred forty-four OSA participants (82.8% men; mean age, 53.1 years; mean Apnea Hypopnea Index with CPAP, 4.2/h; baseline ESS score, 14.7) were randomized to pitolisant (n = 183) or placebo (n = 61). ESS significantly decreased with pitolisant compared with placebo (-2.6; 95% CI, -3.9 to -1.4; P < .001), and the rate of responders to therapy (ESS ≤ 10 or change in ESS ≥ 3) was significantly higher with pitolisant (71.0% vs 54.1%; P = .013). Adverse event occurrence (mainly headache and insomnia) was higher in the pitolisant group compared with the placebo group (47.0% and 32.8%, respectively; P = .03). No cardiovascular or other significant safety concerns were reported.Interpretation: Pitolisant used as adjunct to CPAP therapy for OSA with residual sleepiness despite good CPAP adherence significantly reduced subjective and objective sleepiness and improved participant-reported outcomes and physician-reported disease severity

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

International audienc